Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 4249.23%.

  • Insight Molecular Diagnostics' EBIT Margin rose 75029400.0% to 4249.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 1392.91%, marking a year-over-year increase of 47556100.0%. This contributed to the annual value of 3245.14% for FY2024, which is 15727500.0% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' EBIT Margin is 4249.23%, which was up 75029400.0% from 1900.0% recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' EBIT Margin peaked at 1969.7% during Q1 2023, and registered a low of 11752.17% during Q3 2024.
  • Moreover, its 5-year median value for EBIT Margin was 1791.36% (2023), whereas its average is 2575.16%.
  • In the last 5 years, Insight Molecular Diagnostics' EBIT Margin surged by 516830700bps in 2021 and then plummeted by -102339900bps in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' EBIT Margin stood at 994.15% in 2021, then tumbled by -328bps to 4251.09% in 2022, then dropped by -21bps to 5152.55% in 2023, then soared by 56bps to 2262.92% in 2024, then plummeted by -88bps to 4249.23% in 2025.
  • Its EBIT Margin was 4249.23% in Q3 2025, compared to 1900.0% in Q2 2025 and 318.01% in Q1 2025.